GSK plc (GLAXF)

21.1000
+0.2750(+1.32%)
  • Volume:
    3,856
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    21.1000 - 21.9800

GLAXF Overview

Prev. Close
20.825
Day's Range
21.1-21.98
Revenue
-
Open
21.49
52 wk Range
18.18-23.47
EPS
-
Volume
3,856
Market Cap
109.06B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
208,762
P/E Ratio
15.54
Beta
-
1-Year Change
5.08%
Shares Outstanding
5,060,248,734
Next Earnings Date
-
What is your sentiment on GSK plc?
or
Market is currently closed. Voting is open during market hours.

GSK plc Analysis

GSK plc Company Profile

GSK plc Company Profile

Employees
90096

GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellNeutralBuy
Technical IndicatorsBuyBuyBuyNeutralStrong Buy
SummaryBuyNeutralNeutralNeutralStrong Buy
  • This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move
    2
    • Moving closer to my 1800 tgt (posted on March 30). This stock pays very generous dividend I have to say
      3
      • ex-div in 13 days time. why risk selling now when you might not get back on the boat? pretty sure the company split will reach equivalent of 2000+ for the two new companies.
        1
        • 1587.80 looking at my previous comment "what do i know" near yearly HIGHS
          0
          • Breakout. Strong buy
            0
            • 1399.60p described as a good Divi stock but where's the potential capital growth... will wait for sub 1200.00p
              2
              • The current CEO seems to have lost confidence, time for a change to inject new life into the company
                6
                • the news from today remarked that investors present applauded during the event.
                  0
                • the question is what percentage of GSK shareholders attended, most big investors gont go to such events
                  0
                • while true, until we know who attended it's hard to gauge lost confidence. at the start of the day pre share holder day, the share price was 20p down, that swung to 40p up at one point, hardly signals negativity
                  0
              • Seems to me that a stake is being built, especially from the area of £13.25 upwards. We already have the "activist" investment fund but another buyer is around. Seems similar to whats been happening in BT shares over the last few weeks. Stay long and collect dividends on the way. Hopefully
                1
                • what will happen when the split happens in 2022?!
                  0
              • MINAYULSK
                0
                • There is absolutely value at its 12m lows 1190.00 so I'm waiting for any bad news and will buy in the dips.... Are THEY PAYING A Dividend???
                  3
                  • Yes, 23p per share last time round in April
                    0
                  • I believe the next dividend, may 20th, is 19p.
                    0
                  • thanks Paul , Simon.
                    0